ORIGINAL ARTICLE

ASIAN JOURNAL OF MEDICAL SCIENCES

Cancer incidence among patients attending a tertiary care cancer hospital in central India – A retrospective study



Lalit Mohan Patel¹, Kunal Peepre², Haritha VS³, Yogesh Tiwari⁴

¹Assistant Professor, Department of Radiation Oncology, ⁴Assistant Professor, Department of Surgical Oncology, State Cancer Institute, Netaji Subhash Chandra Bose Medical College, Jabalpur, ²Assistant Professor, Department of Community Medicine, Birsa Munda Government Medical College, Shahdol, Madhya Pradesh, ³Senior Resident, Department of Radiation Oncology, Government T.D Medical College, Alappuzha, Kerala, India

Submission: 04-06-2023

Revision: 28-09-2023

Publication: 01-11-2023

Access this article online

http://nepjol.info/index.php/AJMS

DOI: 10.3126/ajms.v14i11.53940

Copyright (c) 2023 Asian Journal of

This work is licensed under a Creative

Commons Attribution-NonCommercial

4.0 International License

E-ISSN: 2091-0576

P-ISSN: 2467-9100

Medical Sciences

Website:

ABSTRACT

Background: Cancer is a leading cause of mortality and morbidity in the world. Cancer incidence varies widely throughout India from east to west and from north to south making the prevention and control programs difficult the alarming increase of cancer cases in low and middle-income countries like India warrants us to have a better knowledge about the transition in the epidemiology in various parts of the country. Aims and Objectives: The aim of this study was to assess the incidence of different cancers among patients visiting a tertiary care cancer hospital in central India. Materials and Methods: The data were collected retrospectively from the medical record database of a tertiary care cancer hospital in Central India from the time period between January 2017 and December 2021. A total of 13011 patients were registered at our hospital between this time period. Data were analyzed for the site of disease and tabulated, and then, the percentage distribution was calculated. Results: Head-and-neck cancer was the most commonly reported one followed by cervical cancer and breast cancer. Among gynecological malignancies, cervical cancer dominated the spectrum followed by ovarian cancer and endometrial cancer. Tobacco-related cancers were seen in high number each year. Less commonly reported cancers were that of urethral, adrenal, germ cell tumors, and choriocarcinoma followed by that of eye and ear. **Conclusion:** There is an urgent need to set up stringent hospital-based and population-based cancer registration system to understand the profile of cancer in each geographical region for a better understanding and implementation of cancer control programs.

Key words: Cancer epidemiology; Incidence; Central India; Mortality; Morbidity

INTRODUCTION

The low- and middle-income countries (LMICs) are undergoing an epidemiological transition wherein the burden of communicable diseases is declining and noncommunicable diseases like cancers are rising.¹ By 2025, around 20 million cancer cases are expected in LMICs.²

A considerable variation in the incidence of cancers is there between high-income countries (HICs) and LMICs.³ In both men and women, the incidence varies from 95/10 000 in the LMICs to over 571/100 000 in the HIC countries.⁴ The

situation is dramatically altering in LMICs over the past few decades, especially due to lifestyle changes, industrialization, migration of population from rural areas to cities, and increased life expectancy.^{5,6} Non-communicable diseases are responsible for more than three-fifths of the deaths globally (36 million) which is largely contributed by cardiovascular diseases (48%), cancers (21%), chronic respiratory diseases (4.2 million deaths), and diabetes mellitus (1.3 million deaths).

The information on the number of new cancer cases and cancer deaths is not available from major regions of the world. The coverage was quite unequal, as in Latin America, 95%

Address for Correspondence:

DR. Haritha VS, Senior Resident, Department of Radiation Oncology, Government T.D. Medical College, Alappuzha, Kerala, India. **Mobile:** +91-9446047048. **E-mail:** vsharitha26@gmail.com

of the population was covered, whereas in Asia, it was only 9%.⁷ In India, to identify the burden of cancers, a Cancer Registry Programme was started by the Indian Council of Medical Research in 1982 with an objective of determining the magnitude and pattern of various cancers. It started with six cancer registries, three population-based cancer registries (PBCRs) and three hospital-based cancer registries. The Indian Council of Medical Research and the National Centre for Disease Informatics and Research published the NCRP report 2020 which included 28 PBCRs and 58 hospital-based cancer registries. It gives an overview of the cancer incidence patterns across India between 2012 and 2016.⁸

The cancer incidence differs dramatically based on the geographical location within India. The highest cancer incidence was observed in Northeast India, with the most common cancers being nasopharyngeal, hypopharyngeal, esophageal, stomach, liver, gallbladder, laryngeal, lung, breast, and cervical cancers. There is an overall trend suggesting a transition to lifestyle-related cancers such as breast and colorectal cancers. The incidence of infection-related cancers such as cervical and stomach cancers is declining.⁹

Shetty et al.⁸ in their study have looked into the geographical distribution of cancers and have reported the common (oral, breast, cervical, and lung) and emerging (prostate, ovarian, and endometrial) cancers across India to assess if national efforts can be directed accordingly. They selected six PBCRs with the highest number of patients from each zone in the country (north, south, east, west, central, and northeast), which included a total of 187891 patients. The report highlighted that oral, cervical, and breast cancers constitute the major cancer burden (more than 50%) and that there are incommensurately high incidence rates of cancer in Northeast Baghelkhand region, and Malajkhand region of central India. They also reported that the incidence of lung, breast, prostate, and colorectal cancers is increasing.

The primary purpose of this study is to find the pattern of incidence of cancer in the Central India region which caters cancer care to a large region including Mahakoshal region, Vindhya region, Bundelkhand region, Baghelkhand region, and Malajkhand region of central India.

Aims and objectives

The aim of this study was to assess the incidence of different cancers among patients visiting a tertiary care cancer hospital in central India.

MATERIALS AND METHODS

Study design

The present retrospective study was carried out at a tertiary care cancer hospital in Madhya Pradesh in central India.

13011 histopathologically proven patients of malignancy were registered during the time period January 2017–December 2021.

Data collection method

The data regarding the newly registered cases were obtained from the medical record database maintained at the hospital.

Data analysis

Data analysis was done using Microsoft Excel sheet and percentage analysis of each cancer was done.

Inclusion criteria

A patient who is histopathologically proven of cancer (including new cases as well as recurrence cases) and who is newly registered at our center.

Exclusion criteria

A patient who is not histopathologically proven and who is not registered at our center.

RESULTS

There were 13011 cancer cases registered during the time period from January 2017 to December 2021. Among them, head-and-neck cancer was the most common (30.67%) followed by cervical cancer (15.8%) and breast cancer (12.4%) (Table 1 and Figures 1 and 2) Among gynecological cancers which constituted 19.7% of the total cases, cervical cancer was the most common (80.4%) followed by ovarian cancer (13.7%) and endometrial cancer (4%) (Figure 3). Tobacco-related cancers almost dominated. Less commonly seen were urethral cancer (0.007%), germ cell tumors (0.03%), choriocarcinoma (0.03%), eye (0.17%), and ear cancers (0.12%). Hematological malignancies constituted 5.7% of the total.

DISCUSSION

India exhibits heterogeneity in cancer. Approximately 70% of cancers in India were potentially preventable through modifiable risk factors.¹⁰ Lung (9 PBCRs), mouth (9 PBCRs), esophagus (5 PBCRs), stomach (4 PBCRs), and nasopharynx (1 PBCR) cancers were the most common cancers in men.¹¹ Lung cancer was the leading site in metropolitan cities and the southern region, whereas mouth cancer was the leading site in the West and Central regions. Lung cancer and oral cancer were the most common cancers of the esophagus, stomach, and nasopharynx were the leading sites in the Northeastern region of India with the cancer incidence pattern being

Cancer site Total % Skin 115 0.088 Central nervous system 221 1.69 Eye and orbit 23 0.17 Ear 16 0.12 Head and neck 3991 30.67 Thyroid 46 0.35 Lung, mediastinum, heart 496 3.8 Breast 1614 12.4 Gl system 1955 100 Esophagus 507 3.89 GIT 807 6.2 Hepatobiliary 641 4.9 Genitourinary system 464 464 Kidney and Ureter 61 0.46 Bladder 137 1.05 Urethra 1 0.007 Testis and scrotum 69 0.53 Prostrate 137 1.05 Urethra 20 0.45 Gynecological malignancies 2567 Ovary 354 2.72 Choriocarcinoma 4	Table 1: Site wise distribution and incidence ofvarious cancers			
Skin 115 0.088 Central nervous system 221 1.69 Eye and orbit 23 0.17 Ear 16 0.12 Head and neck 3991 30.67 Thyroid 46 0.35 Lung, mediastinum, heart 496 3.8 Breast 1614 12.4 GI system 1955 1614 Esophagus 507 3.89 GIT 807 6.2 Hepatobiliary 641 4.9 Genitourinary system 464 Kidney and Ureter Bladder 137 1.05 Urethra 1 0.007 Testis and scrotum 69 0.53 Prostrate 137 1.05 Qynecological malignancies 2567 0 Ovary 354 2.72 Choriocarcinoma 4 0.03 Endometrium/uterus 104 0.079 Cervix 2064 15.8 <td< th=""><th>Cancer site</th><th>Total</th><th>%</th></td<>	Cancer site	Total	%	
Central nervous system 221 1.69 Eye and orbit 23 0.17 Ear 16 0.12 Head and neck 3991 30.67 Thyroid 46 0.35 Lung, mediastinum, heart 496 3.8 Breast 1614 12.4 Gl system 1955 1955 Esophagus 507 3.89 GIT 807 6.2 Hepatobiliary 641 4.9 Genitourinary system 464 464 Kidney and Ureter 61 0.46 Bladder 137 1.05 Urethra 1 0.007 Testis and scrotum 69 0.53 Prostrate 137 1.05 Penis 59 0.45 Gynecological malignancies 2567 0 Ovary 354 2.72 Choriocarcinoma 4 0.03 Endometrium/uterus 104 0.079 Cerv	Skin	115	0.088	
Eye and orbit 23 0.17 Ear 16 0.12 Head and neck 3991 30.67 Thyroid 46 0.35 Lung, mediastinum, heart 496 3.8 Breast 1614 12.4 Gl system 1955 Esophagus 507 3.89 GIT 807 6.2 Hepatobiliary 641 4.9 Genitourinary system 464 Kidney and Ureter 61 0.46 Bladder 137 1.05 Urethra 1 0.007 Testis and scrotum 69 0.53 Prostrate 137 1.05 Penis 59 0.45 Gynecological malignancies 2567 Ovary 354 2.72 Choriocarcinoma 4 0.03 Endometrium/uterus 104 0.079 Cervix 2064 15.8 Vagina 20 0.15 Vulva 21 0.16 Hematological malignancies 749 Lymphoma	Central nervous system	221	1.69	
Ear 16 0.12 Head and neck 3991 30.67 Thyroid 46 0.35 Lung, mediastinum, heart 496 3.8 Breast 1614 12.4 Gl system 1955 Esophagus 507 3.89 GIT 807 6.2 Hepatobiliary 641 4.9 Genitourinary system 464 Kidney and Ureter 61 0.46 Bladder 137 1.05 Urethra 1 0.007 Testis and scrotum 69 0.53 Prostrate 137 1.05 Penis 59 0.45 Gynecological malignancies 2567 Ovary 354 2.72 Choriocarcinoma 4 0.03 Endometrium/uterus 104 0.079 Cervix 2064 15.8 Vagina 20 0.15 Vulva 21 0.16 1 2 Leukemia 407 3.12 Plasma cell disorders 81 0.62	Eye and orbit	23	0.17	
Head and neck 3991 30.67 Thyroid 46 0.35 Lung, mediastinum, heart 496 3.8 Breast 1614 12.4 Gl system 1955 1955 Esophagus 507 3.89 GIT 807 6.2 Hepatobiliary 641 4.9 Genitourinary system 464 464 Kidney and Ureter 61 0.46 Bladder 137 1.05 Urethra 1 0.007 Testis and scrotum 69 0.53 Prostrate 137 1.05 Penis 59 0.45 Gynecological malignancies 2567 0 Ovary 354 2.72 Choriocarcinoma 4 0.03 Endometrium/uterus 104 0.079 Cervix 2064 15.8 Vagina 20 0.15 Vulva 21 0.16 Hematological malignanci	Ear	16	0.12	
Thyroid 46 0.35 Lung, mediastinum, heart 496 3.8 Breast 1614 12.4 GI system 1955	Head and neck	3991	30.67	
Lung, mediastinum, heart 496 3.8 Breast 1614 12.4 GI system 1955	Thyroid	46	0.35	
Breast 1614 12.4 GI system 1955 Esophagus 507 3.89 GIT 807 6.2 Hepatobiliary 641 4.9 Genitourinary system 464	Lung, mediastinum, heart	496	3.8	
GI system 1955 Esophagus 507 3.89 GIT 807 6.2 Hepatobiliary 641 4.9 Genitourinary system 464	Breast	1614	12.4	
Esophagus 507 3.89 GIT 807 6.2 Hepatobiliary 641 4.9 Genitourinary system 464	GI system	1955		
GIT 807 6.2 Hepatobiliary 641 4.9 Genitourinary system 464 Kidney and Ureter 61 0.46 Bladder 137 1.05 Urethra 1 0.007 Testis and scrotum 69 0.53 Prostrate 137 1.05 Gynecological malignancies 2567 0 Ovary 354 2.72 Choriocarcinoma 4 0.03 Endometrium/uterus 104 0.079 Cervix 2064 15.8 Vagina 20 0.15 Vulva 21 0.16 Hematological malignancies 749 2 Lymphoma 261 2 Leukemia 407 3.12 Plasma cell disorders 81 0.62 Sarcoma 304 3 Soft tissue sarcoma 47 0.36 Pediatric malignancies 64 0.49 Non-malignant condit	Esophagus	507	3.89	
Hepatobiliary 641 4.9 Genitourinary system 464	GIT	807	6.2	
Genitourinary system 464 Kidney and Ureter 61 0.46 Bladder 137 1.05 Urethra 1 0.007 Testis and scrotum 69 0.53 Prostrate 137 1.05 Penis 59 0.45 Gynecological malignancies 2567 - Ovary 354 2.72 Choriocarcinoma 4 0.03 Endometrium/uterus 104 0.079 Cervix 2064 15.8 Vagina 20 0.15 Vulva 21 0.16 Hematological malignancies 749 - Lymphoma 261 2 Leukemia 407 3.12 Plasma cell disorders 81 0.62 Sarcoma 304 - Soft tissue sarcoma 477 0.36 Pediatric malignancies 64 0.49 Non-malignant conditions 3 0.02 Carcino	Hepatobiliary	641	4.9	
Kidney and Ureter 61 0.46 Bladder 137 1.05 Urethra 1 0.007 Testis and scrotum 69 0.53 Prostrate 137 1.05 Penis 59 0.45 Gynecological malignancies 2567 272 Ovary 354 2.72 Choriocarcinoma 4 0.03 Endometrium/uterus 104 0.079 Cervix 2064 15.8 Vagina 20 0.15 Vulva 21 0.16 Hematological malignancies 749 2 Lymphoma 261 2 Leukemia 407 3.12 Plasma cell disorders 81 0.62 Sarcoma 304 3 Soft tissue sarcoma 47 0.36 Pediatric malignancies 64 0.49 Non-malignant conditions 3 0.02 Carcinoma of unknown primary 378 2.9 <td>Genitourinary system</td> <td>464</td> <td></td>	Genitourinary system	464		
Bladder 137 1.05 Urethra 1 0.007 Testis and scrotum 69 0.53 Prostrate 137 1.05 Penis 59 0.45 Gynecological malignancies 2567	Kidney and Ureter	61	0.46	
Urethra 1 0.007 Testis and scrotum 69 0.53 Prostrate 137 1.05 Penis 59 0.45 Gynecological malignancies 2567	Bladder	137	1.05	
Testis and scrotum 69 0.53 Prostrate 137 1.05 Penis 59 0.45 Gynecological malignancies 2567 Ovary 354 2.72 Choriocarcinoma 4 0.03 Endometrium/uterus 104 0.079 Cervix 2064 15.8 Vagina 20 0.15 Vulva 21 0.16 Hematological malignancies 749 2 Lymphoma 261 2 Leukemia 4077 3.12 Plasma cell disorders 81 0.62 Sarcoma 304 2 Soft tissue sarcoma 477 0.36 Pediatric malignancies 64 0.49 Non-malignant conditions 3 0.02 Carcinoma of unknown primary 378 2.9 Germ cell tumors 5 0.03 Total 13011 13011	Urethra	1	0.007	
Prostrate 137 1.05 Penis 59 0.45 Gynecological malignancies 2567 Ovary 354 2.72 Choriocarcinoma 4 0.03 Endometrium/uterus 104 0.079 Cervix 2064 15.8 Vagina 20 0.15 Vulva 21 0.16 Hematological malignancies 749 2 Lymphoma 261 2 Leukemia 407 3.12 Plasma cell disorders 81 0.62 Sarcoma 304 257 1.97 Bone sarcoma 47 0.36 2 Pediatric malignancies 64 0.49 0.02 Carcinoma of unknown primary 378 2.9 3 Germ cell tumors 5 0.03 3	Testis and scrotum	69	0.53	
Penis 59 0.45 Gynecological malignancies 2567 Ovary 354 2.72 Choriocarcinoma 4 0.03 Endometrium/uterus 104 0.079 Cervix 2064 15.8 Vagina 20 0.15 Vulva 21 0.16 Hematological malignancies 749 2 Lymphoma 261 2 Leukemia 407 3.12 Plasma cell disorders 81 0.62 Sarcoma 304 304 Soft tissue sarcoma 477 0.36 Pediatric malignancies 64 0.49 Non-malignant conditions 3 0.02 Carcinoma of unknown primary 378 2.9 Germ cell tumors 5 0.03 Total 13011 13011	Prostrate	137	1.05	
Gynecological malignancies2567Ovary3542.72Choriocarcinoma40.03Endometrium/uterus1040.079Cervix206415.8Vagina200.15Vulva210.16Hematological malignancies749Lymphoma2612Leukemia4073.12Plasma cell disorders810.62Sarcoma304Soft tissue sarcoma2571.97Bone sarcoma470.36Pediatric malignancies640.49Non-malignant conditions30.02Carcinoma of unknown primary3782.9Germ cell tumors50.03Total13011	Penis	59	0.45	
Ovary 354 2.72 Choriocarcinoma 4 0.03 Endometrium/uterus 104 0.079 Cervix 2064 15.8 Vagina 20 0.15 Vulva 21 0.16 Hematological malignancies 749	Gynecological malignancies	2567		
Choriocarcinoma 4 0.03 Endometrium/uterus 104 0.079 Cervix 2064 15.8 Vagina 20 0.15 Vulva 21 0.16 Hematological malignancies 749	Ovary	354	2.72	
Endometrium/uterus 104 0.079 Cervix 2064 15.8 Vagina 20 0.15 Vulva 21 0.16 Hematological malignancies 749 1 Lymphoma 261 2 Leukemia 407 3.12 Plasma cell disorders 81 0.62 Sarcoma 304 197 Bone sarcoma 257 1.97 Bone sarcoma 47 0.36 Pediatric malignancies 64 0.49 Non-malignant conditions 3 0.02 Carcinoma of unknown primary 378 2.9 Germ cell tumors 5 0.03 Total 13011 13011	Choriocarcinoma	4	0.03	
Cervix 2064 15.8 Vagina 20 0.15 Vulva 21 0.16 Hematological malignancies 749 Lymphoma 261 2 Leukemia 407 3.12 Plasma cell disorders 81 0.62 Sarcoma 304	Endometrium/uterus	104	0.079	
Vagina200.15Vulva210.16Hematological malignancies749Lymphoma2612Leukemia4073.12Plasma cell disorders810.62Sarcoma3040.36Soft tissue sarcoma2571.97Bone sarcoma470.36Pediatric malignancies640.49Non-malignant conditions30.02Carcinoma of unknown primary3782.9Germ cell tumors50.03Total13011	Cervix	2064	15.8	
Vulva210.16Hematological malignancies749Lymphoma2612Leukemia4073.12Plasma cell disorders810.62Sarcoma3040.62Soft tissue sarcoma2571.97Bone sarcoma470.36Pediatric malignancies640.49Non-malignant conditions30.02Carcinoma of unknown primary3782.9Germ cell tumors50.03Total13011	Vagina	20	0.15	
Hematological malignancies749Lymphoma2612Leukemia4073.12Plasma cell disorders810.62Sarcoma3040.62Soft tissue sarcoma2571.97Bone sarcoma470.36Pediatric malignancies640.49Non-malignant conditions30.02Carcinoma of unknown primary3782.9Germ cell tumors50.03Total13011	Vulva	21	0.16	
Lymphoma2612Leukemia4073.12Plasma cell disorders810.62Sarcoma304Soft tissue sarcoma2571.97Bone sarcoma470.36Pediatric malignancies640.49Non-malignant conditions30.02Carcinoma of unknown primary3782.9Germ cell tumors50.03Total13011	Hematological malignancies	749		
Leukemia4073.12Plasma cell disorders810.62Sarcoma304Soft tissue sarcoma2571.97Bone sarcoma470.36Pediatric malignancies640.49Non-malignant conditions30.02Carcinoma of unknown primary3782.9Germ cell tumors50.03Total13011	Lymphoma	261	2	
Plasma cell disorders810.62Sarcoma304Soft tissue sarcoma2571.97Bone sarcoma470.36Pediatric malignancies640.49Non-malignant conditions30.02Carcinoma of unknown primary3782.9Germ cell tumors50.03Total13011	Leukemia	407	3.12	
Sarcoma304Soft tissue sarcoma2571.97Bone sarcoma470.36Pediatric malignancies640.49Non-malignant conditions30.02Carcinoma of unknown primary3782.9Germ cell tumors50.03Total13011	Plasma cell disorders	81	0.62	
Soft tissue sarcoma2571.97Bone sarcoma470.36Pediatric malignancies640.49Non-malignant conditions30.02Carcinoma of unknown primary3782.9Germ cell tumors50.03Total13011	Sarcoma	304		
Bone sarcoma470.36Pediatric malignancies640.49Non-malignant conditions30.02Carcinoma of unknown primary3782.9Germ cell tumors50.03Total13011	Soft tissue sarcoma	257	1.97	
Pediatric malignancies640.49Non-malignant conditions30.02Carcinoma of unknown primary3782.9Germ cell tumors50.03Total13011	Bone sarcoma	47	0.36	
Non-malignant conditions30.02Carcinoma of unknown primary3782.9Germ cell tumors50.03Total13011	Pediatric malignancies	64	0.49	
Carcinoma of unknown primary3782.9Germ cell tumors50.03Total13011	Non-malignant conditions	3	0.02	
Germ cell tumors50.03Total13011	Carcinoma of unknown primary	378	2.9	
Total 13011	Germ cell tumors	5	0.03	
	Total	13011		

different from the rest of India but it is quite similar to the incidence pattern seen in the Southeast Asian region.¹²

Cancer of the breast (19 PBCRs) and cervix uteri (7 PBCRs) are the most common cancers reported in women. The highest burden of breast cancer was observed in metropolitan cities. There is an increase in the trend of breast cancer incidence, whereas cervix uteri cancer is on the decline. A steady increase in breast cancer in most of the PBCRs including newer ones poses a great health challenge to women in India.¹³ At present, breast cancer and cervix uteri are the leading sites of cancer among women in India, posing an important public health problem that needs important input from various health and other agencies to tackle.¹⁴ This study too shows similar results in terms of the incidence of breast and cervical cancer.

The most common risk factor studied is tobacco in the form of smoking and smokeless, which is most commonly seen in the Indian subcontinent.¹⁵ The use of tobacco in its various forms is considered to be a risk factor in 45% male cancers and 17% female cancers in India.¹⁶ There are cancers of several anatomic sites which are known to be associated with the use of tobacco.¹⁰ Based on PBCR data, almost one-third of the cancers were known to be associated with the use of tobacco in India. India state-level disease burden initiative cancer collaborators estimate that tobacco use was the highest contributing risk factor for cancer in India. In India, lung cancer can be attributed to tobacco.¹⁷



Figure 1: The distribution of various cancers as per site



Figure 2: The site wise incidence of various cancers



Figure 3: The subsite incidence of various gyneacological malignancies

As it is difficult to obtain information on the clinical extent of disease and treatment from PBCRs, the hospital database is used for such an analysis. Majority of breast and cervix uteri cancers were diagnosed at a locally advanced stage. Two-thirds of the patients with head-and-neck cancer were diagnosed at the locoregional stage. Multimodality was the most common treatment given for breast and head-and-neck cancers.¹¹ A multi-institutional study estimated that 65% of new head-and-neck cancers with locally advanced disease did not receive the benefit of optimal treatment which resulted in poor survival.¹⁸

Less than one-fifth of lung and stomach cancers were diagnosed as being localized only.¹¹ A hospital-based study from northern India showed that 90% of patients with lung cancer were diagnosed at an advanced stage and there was a delay in diagnostic evaluation and treatment.¹⁹ Creating cancer awareness, preventing risk factors, and improving access to care among people would result in downstaging of cancer.¹¹ The rate of increase in the incidence of cancer of the lung among women is a glaring calling for systematic evidence-based and focused anti-tobacco campaigns targeting the urban woman. A large proportion of tobacco-

related cancers can be prevented by anti-tobacco programs. Teenage students need to be targeted as most of them pick up habits at this time. Legislation has to be enforced for prohibiting tobacco advertisements and sale of tobacco to youngsters. Prevention of cancers through the reduction of tobacco use should be an important strategy of the National Cancer Control Programme of India.²⁰

A multidisciplinary approach to cancer treatment is essential and this has to be made available at all Regional Cancer Centers. The services of a trained surgeon and a clinical Oncologist are needed to plan the most appropriate treatment. Efforts should be made to reduce the waiting time for cancer patients to get any cancer-directed treatments. An essential drug list has to be prepared for cancer chemotherapy and chemotherapy services for common cancers have to be made available in all centers. More than 80% of cancers in India present in advanced stages and palliative care and pain relief are essential to provide a good quality of life for these patients.²⁰

Limitations of the study

This study covers only a small proportion of the population in Central India. Hence, a larger study covering the whole population is needed to authenticate the results.

CONCLUSION

This study provides a framework on the incidence and trends of various cancers in Central India which showed that head-and-neck cancers dominated followed by cervical and breast cancer. The estimated rise in cancer in 2030 could only be reduced by a multidisciplinary approach by including awareness programs, organizing screening camps at all levels, taking preventive measures, and making treatment facilities available for each citizen in the country.

ACKNOWLEDGMENTS

Nil.

REFERENCES

1. Kanavos P. The rising burden of cancer in the developing world. Ann Oncol. 2006;17 Suppl 8:i15-23.

https://doi.org/10.1093/annonc/mdl983

 Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-E386.

https://doi.org/10.1002/ijc.29210

 GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211-1259.

https://doi.org/10.1016/S0140-6736(17)32154-2

- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492
- Badwe RA, Dikshit R, Laversanne M and Bray F. Cancer incidence trends in India. Jpn J Clin Oncol. 2014;44(5):401-407. https://doi.org/10.1093/ijco/hyu040
- Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A systematic analysis for the global burden of disease study. JAMA Oncol. 2018;4(11):1553-1568.

https://doi.org/10.1001/jamaoncol.2018.2706

- 7. Boyle P and Levin B, editors. World Cancer Report 2008. France: IARC Publications; 2008.
- Shetty R, Mathew RT and Vijayakumar M. Incidence and patterns of distribution of cancer in India: A secondary data analysis from six population-based cancer registries. Cancer Res Stat Treat. 2020;3(4):678-682.
- 9. Sirohi B and Mathew A. Patterns of cancer incidence in India What next? Cancer Res Stat Treat. 2020;3:790-2.
- WHO. Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs. Vol. 1-42. Lyon, France: IARC; 1987.
- Mathur P, Sathishkumar K, Chaturvedi M, Das P, Sudarshan KL, Santhappan S, et al. Cancer Statistics, 2020: Report from national cancer registry programme, India. JCO Glob Oncol. 2020;6:1063-1075. https://doi.org/10.1200/GO.20.00122
- Sharma JD, Kalit M, Nirmolia T, Saikia SP, Sharma A and Barman D. Cancer: Scenario and relationship of different geographical areas of the globe with special reference to North East-India. Asian Pac J Cancer Prev. 2014;15(8):3721-3729. https://doi.org/10.7314/apjcp.2014.15.8.3721
- Chaturvedi M, Vaitheeswaran K, Satishkumar K, Das P, Stephen S and Nandakumar A. Time trends in breast cancer among Indian women population: An analysis of population based cancer registry data. Indian J Surg Oncol. 2015;6(4):427-434. https://doi.org/10.1007/s13193-015-0467-z
- 14. Takiar R. Status of breast and cervix cancer in selected registries of India. Ann Womens Health. 2018;2(1):1012.
- Ramadas K, Sauvaget C, Thomas G, Fayette JM, Thara S and Sankaranarayanan R. Effect of tobacco chewing, tobacco smoking and alcohol on all-cause and cancer mortality: A cohort study from Trivandrum, India. Cancer Epidemiol. 2010;34(4):405-412.

https://doi.org/10.1016/j.canep.2010.04.006

- Sinha DN, Abdulkader RS and Gupta PC. Smokeless tobaccoassociated cancers: A systematic review and meta-analysis of Indian studies. Int J Cancer. 2016;138(6):1368-1379. https://doi.org/10.1002/ijc.29884
- India State-Level Disease Burden Initiative Cancer Collaborators. The burden of cancers and their variations across the states of India: The Global Burden of Disease Study 1990-2016. Lancet Oncol. 2018;19(10):1289-1306.

https://doi.org/10.1016/S1470-2045(18)30447-9

Asian Journal of Medical Sciences | Nov 2023 | Vol 14 | Issue 11

 Nandakumar A and Nandakumar A. Survival in head and neck cancers - results of a multi- institution study. Asian Pac J Cancer Prev. 2016;17(4):1745-1754.

https://doi.org/10.7314/apjcp.2016.17.4.1745

19. Chandra S, Mohan A, Guleria R, Singh V and Yadav P. Delays

during the diagnostic evaluation and treatment of lung cancer. Asian Pac J Cancer Prev. 2009;10(3):453-456.

 Takiar R, Nadayil D and Nandakumar A. Projections of number of cancer cases in India (2010-2020) by cancer groups. Asian Pac J Cancer Prev. 2010;11(4):1045-1049.

Authors' Contributions:

LMP- Definition of intellectual content, literature survey, prepared first draft of manuscript, data collection, data analysis, manuscript preparation; KP- Statistical analysis and interpretation; HVS- Concept, design, clinical protocol, manuscript preparation, editing, and manuscript revision; YT- Literature survey, coordination, and manuscript revision.

Work attributed to:

Department of Radiation Oncology, Netaji Subhash Chandra Bose Medical College, Jabalpur, Madhya Pradesh, India.

Orcid ID:

Lalit Mohan Patel - ⁽ⁱ⁾ https://orcid.org/0000-0002-3865-0901 Kunal Peepre - ⁽ⁱ⁾ https://orcid.org/0000-0003-0318-5357 Haritha VS - ⁽ⁱ⁾ https://orcid.org/0000-0001-9878-1914 Yogesh Tiwari - ⁽ⁱ⁾ https://orcid.org/0000-0001-7783-6744

Source of Support: Nil, Conflicts of Interest: None declared.